HPV16‐related pigmented Bowen's disease on the palm
C. Nakayama,H. Hata,K. Imafuku,E. Toyonaga,H. Shimizu
DOI: https://doi.org/10.1111/jdv.12628
2016-01-01
Journal of the European Academy of Dermatology and Venereology
Abstract:four elderly patients treated with MC. All reported patients were diagnosed with advanced CTCLs [two tumour-stage mycosis fungoides (MF) and two S ezary syndrome (SS)] based on the current WHO-EORTC classification for cutaneous lymphomas and had refractoriness to at least two prior conventional systemic therapies. Other more aggressive therapeutic options were not considered appropriate due to medical comorbidities and patients’ frailty. MC was administered according to previous reports in refractory/relapsed systemic lymphoma, starting with a combination of three oral cytotoxic drugs: prednisone 15– 30 mg after breakfast; cyclophosphamide 50 mg after lunch, procarbazine 50 mg or etoposide 50 mg at bedtime. A complete blood count, biochemical profile and clinical examination were performed every 2–4 weeks to monitor therapy responses and safety. The patient’s characteristics and treatment results are shown in Table 1. MC was well tolerated by all patients. Overall toxicity, mainly related with steroids, was mild and no serious unexpected adverse events were recorded. MC reduced tumours (Fig. 1), which often showed ulceration and helped to control lymph nodes enlargement and neoplastic T cells in peripheral blood in patients with SS. A clear-cut improvement of ulcerated tumours in two patients was observed along the first month of treatment. The duration of response ranged from 3 to 12 months (median, 6 months). Three patients developed progressive disease and died at 11, 9 and 14 months of follow-up after completing 4.5, 7 and 12 months of MC respectively. One patient died with concomitant bacterial pneumonia, in spite of normal neutrophil count and previous oral antibiotics administration for skin infections. Advanced MF/SS (stages IIB–IVB) is often treatment refractory and therapy is aimed at reducing the tumour burden, delaying disease progression and preserving quality of life. Current management includes immunobiologic, targeted therapies and chemotherapy, but the duration of clinical response is often short. In addition, treatment-associated toxicities can be hazardous particularly in elderly patients. In those patients, often with several medical problems and unable to tolerate more toxic therapies or be included in clinical trials, MC could be a palliative strategy that can help to control temporarily the symptoms of the disease (tumours, ulceration, pruritus and palpable peripheral lymph nodes) without significant toxicity. MC is easy to administer and less expensive than most management modalities used in advanced CTCLs. Since advanced and aggressive CTCLs constitute a therapeutic challenge, the possible role of MC in comparison to conventional therapeutic regimes warrants further investigation in a larger number of patients. It would be important to better assess the risk of infection during MC as patients with advanced CTCL are prone to infection given their underlying immunosuppression. D. L opez Avent ın,* F. Gallardo, B. Sanchez-Gonzalez, R.M. Pujol, A. Salar Department of Dermatology Department of Clinical Haematology, Hospital del Mar – Parc de Salut Mar, Barcelona, Spain *Correspondence: D. L opez Avent ın. E-mail: DLopezAventin@ parcdesalutmar.cat.